Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 30

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 30
---
 16 of the Exchange Act, with respect to their purchases and sales of shares. In addition, we are not required to file annual,
quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are
registered under the Exchange Act.

You can review our SEC filings
and the registration statement by accessing the SEC’s internet site at http://www.sec.gov. We maintain a corporate website at https://www.clearmindmedicine.com/.
Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included
our website address in this prospectus solely as an inactive textual reference.

<div align='center'>S-17</div>

PROSPECTUS

<div align='center'>Clearmind Medicine Inc.

$50,000,000

Common Shares

Subscription Rights

Warrants

Units</div>

We may offer, issue and sell
from time to time up to US $50,000,000 of our Common Shares, subscription rights, or “Subscription Rights,” warrants, or “Warrants,”
and a combination of such securities, separately or as units, or “Units”, in one or more offerings.

We refer to the Common Shares,
Subscription Rights, Warrants and Units, collectively, as the “securities” in this prospectus. We may offer, issue and sell
the securities at an aggregate public offering price that will not exceed 50,000,000.

Each time we sell securities
pursuant to this prospectus, we will provide in a supplement to this prospectus the price and any other material terms of any such offering.
Any prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and
any applicable prospectus supplement, as well as the documents incorporated by reference or deemed incorporated by reference into this
prospectus, carefully before you invest in any securities. This prospectus may not be used to offer or sell securities unless accompanied by a prospectus supplement.

We may, from time to time,
offer to sell the securities, through public or private transactions, directly or through underwriters, agents or dealers, on or off the
Nasdaq Capital Market, or Nasdaq, at prevailing market prices or at privately negotiated prices. If any underwriters, agents or dealers
are involved in the sale of any of these securities, the applicable prospectus supplement will set forth the names of the underwriter,
agent or